Format

Send to

Choose Destination

See 1 citation in Am J Transplant 2016:

Am J Transplant. 2016 May;16(5):1474-9. doi: 10.1111/ajt.13518. Epub 2015 Nov 20.

Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.

Author information

1
Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
2
INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.
3
Université Paul Sabatier, Toulouse, France.
4
Department of Hepatology and Gastroenterology, Toulouse, France.
5
Laboratory of Virology, CHU Purpan, Toulouse, France.
6
MR 152 IRD-Toulouse 3 University, Toulouse, France.
7
Internal Medicine-Digestive Department, CHU Purpan, Toulouse, France.

Erratum in

Abstract

There is no approved therapy for hepatitis C virus (HCV) infection after kidney transplantation, and no data regarding the use of new-generation direct antiviral agents (DAAs) have been published so far. The aims of this pilot study were to assess the efficacy and safety of an interferon-free sofosbuvir-based regimen to treat chronic HCV infection in kidney transplant recipients. Twenty-five kidney transplant recipients with chronic HCV infection were given, for 12 (n = 19) or 24 weeks (n = 6), sofosbuvir plus ribavirin (n = 3); sofosbuvir plus daclatasvir (n = 4); sofosbuvir plus simeprevir, with (n = 1) or without ribavirin (n = 6); sofosbuvir plus ledipasvir, with (n = 1) or without ribavirin (n = 9); and sofosbuvir plus pegylated-interferon plus ribavirin (n = 1). A rapid virological response, defined by undetectable viremia at week 4 after starting DAA therapy, was observed in 22 of the 25 patients (88%). At the end of therapy, HCV RNA was undetectable in all patients. At 4 and 12 weeks after completing DAA therapy, all had a sustained virological response. The tolerance to anti-HCV therapy was excellent and no adverse event was observed. A significant decrease in calcineurin inhibitor levels was observed after HCV clearance. New-generation oral DAAs are efficient and safe to treat HCV infection after kidney transplantation.

KEYWORDS:

clinical research / practice; infection and infectious agents; infectious disease; kidney disease: infectious; kidney transplantation / nephrology; viral: hepatitis C

PMID:
26587971
DOI:
10.1111/ajt.13518
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center